Search

1 to 10 of 749
Sort by

Event
Immuno-Oncology Young Investigators' Forum

Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. (CEC) in collaboration with the Society for Immunotherapy of Cancer. This program is ideally suited for North American-based junior faculty, fellows, and postdoctoral researchers (MDs, DOs,...

 04-16-2020 08:00 - 04-18-2020 20:00 CT
 Houston TX


Web Page
Seattle

Saturday, March 28, 2020 8:30 a.m. PST Organizers: Shailender Bhatia, MD – University of Washington Petros Grivas, MD, PhD – University of Washington ACI-Seattle Program Registration Advanced online registration will be available soon. Onsite registration will be available at the...


Library Entry
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. The authors describe the pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and...


Library Entry
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Hepatitis B virus (HBV) reactivation is commonly seen in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Little is known about the risk of HBV reactivation after chimeric antigen receptor T-cell (CAR T) immunotherapy for the treatment of refractory/relapsed...


Library Entry
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. The authors hypothesized that BoM may influence sensitivity to immunotherapy. They conclude that BoM impairs...


Library Entry
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

Neurologic complications such as myelitis are very rare but extremely deleterious adverse effects of both immunotherapy and radiotherapy. Many recent studies have focused on the possible synergy of these two treatment modalities due to their potential to enhance each other’s immunomodulatory...


Library Entry
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fatal complication. The authors reviewed their institutional...


Library Entry
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Hepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or chemotherapy. However, the safety of anti-programmed cell death (PD) -1 and anti-programmed cell death-ligand 1 (PD-L1) therapy in these patients is...


Event
SITC Cancer Immunotherapy Guidelines – Renal Cell Carcinoma Webinar

On Jan. 7, 2020, join leading experts in cancer immunotherapy as they present an overview of the recently published SITC Cancer Immunotherapy Guidelines – Renal Cell Carcinoma at a live webinar. This FREE CME-, CNE-, CPE-certified webinar provides a chance for healthcare providers who...

 01-07-2020 | 11:00 - 12:00 ET


Web Page
JITC Digest November 2019

Inside this Issue: Letter from the Editor JITC Editor Picks Other Recent JITC ARTICLES Letter from the Editor Dear JITC Readers, You are receiving this email in the weeks after SITC’s 2019 Annual Meeting and Pre-Conference Programs. This year’s meeting was a smashing success, truly...